Relation between bone metastasis in lung cancer and serum IL-6 levels Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
Serum hepcidin and iron are associated with non-small cell lung cancer stage Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
Carbohydrate-induced conformational MUC1 tumor-epitope correlates with improved post-surgical survival of non-small cell lung cancer patients with local or distant metastasis Source: Eur Respir J 2006; 28: Suppl. 50, 150s Year: 2006
Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Markers of angiogenesis in serum are correlating with disease progress in lung cancer Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 229s Year: 2002
Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Biphosphonate, ibantronate improves analgesic therapy in non-small lung cancer (NSCLC) patients with bone metastases Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005